Organic Active Ingredients TRIZ Cases

A 50–100 mg daily serabelisib composition treats vascular malformations while suppressing hyperglycemia during long-term administration.

Specific human-gene 5′ and 3′ UTRs raise recombinant mRNA translation and stability, supporting higher target-protein expression.

Substituted tricyclic compounds selectively bind FKBP isoforms to retain therapeutic activity while avoiding immunosuppressive side effects.

A saliva-based optical biosensor rapidly quantifies cortisol to select patients for GR antagonist therapy in resistant cancer and viral infection.

Brigatinib paired with anti-EGFR antibodies targets C797S-associated NSCLC that resists gefitinib or osimertinib, suppressing tumor growth.

Current ocular neovascular treatments may not stop geographic atrophy progression; selective anti-C5 aptamer therapy slows lesions and can complement VEGF antagonists.

In ESRD, tenapanor inhibits intestinal phosphate absorption while reduced phosphate-binder doses support serum phosphate control and adherence.

Centrifugation removes large glucan particles before drying, producing a fine β-1,3-1,6-glucan powder with high water solubility.

Novel 2-azabicyclo[3.1.1]heptane OX2R agonists address weak metabolic stability and idiosyncratic liver toxicity in narcolepsy treatment.

Daily 90–130 µg of beraprost sodium targets IRIS stage 4 progression and survival outcomes in cats with stage 3 or 4 CKD.

Lipofibroblast-derived EVs deliver natural therapeutic cargo that supports epithelial proliferation while addressing chronic inflammation and lung fibrosis.

C18:1-Leu addresses limited disease modification by reducing amyloid-beta production and increasing microglial plaque clearance.

Specific triazolopyridine substitutions target JAK and BTK inhibition to improve treatment stability and reduce side-effect concerns.

A weighted model prioritizes detected rescue inhalations over airflow data to improve asthma exacerbation risk assessment and support timely intervention.

To address weak insulin stimulation in T2DM, heterocyclic GLP-1 agonists reduce fasting glucose and HbA1c while increasing insulin levels.

Crystalline tromethamine salts address injectable GLP-1 therapy’s compliance limits by improving solubility, stability, and oral bioavailability.

This case shows how aza-, oxa-, and thia-pregnan compounds modulate GABA A receptors to address CNS disorders and drug side effects.

A topical Ophiopogon japonicus hydrolyzate targets inflammation, skin-barrier integrity, and microbiota in atopic dermatitis.

Specific heterocyclic substitutions enhance insulin secretion, suppress glucagon, and improve glucose control in T2DM.

Conflicting GM3 and GD3 effects on iNKT cells are addressed with synthetic NGcGM3 variants that show antitumor and anti-metastatic activity.

A composite pet supplement combines plant ingredients, probiotics, prebiotics, and egg products to support microbiota and digestive health.

A weighted model combines rescue-inhalation counts with airflow measurements to improve COPD exacerbation risk prediction.

Small-molecule pyrrolopyridine derivatives chemically activate Oct4 to induce MET without viral or vector-based modulation.

Novel azetidin-3-ylmethanol derivatives selectively modulate CCR6, addressing weak receptor specificity in inflammation and cancer treatment.

Dimensioned β-1-4-glucan fibers form a temporary barrier during the post-meal reflux window, reducing esophageal exposure.

Replacing cytoplasmic rhodopsin loops helps this chimeric protein improve visual restoration beyond ion-channel rhodopsins alone.

Low oral bioavailability is addressed with a benzene sulfonamide thiazole composition using poly(ethylene glycol), solvent, and water.

Combining an amorphous drug dispersion with external HPMCAS helps maintain physical stability while improving dissolution for poorly water-soluble drugs.

The Formula 1 compound inhibits osteoclast differentiation and production as an alternative approach to bisphosphonate-related side effects.

Alternating treatment and interval sessions lower systemic immunosuppression, enabling inflammation-resolving leukocytes to reach the CNS.

These compounds target Ppif-linked mPTP activity while addressing CYP2D6 inhibition and weak oral bioavailability.

Small-molecule quinolinone amides inhibit myosin crossbridge formation to address HCM obstruction without invasive tissue removal.

Novel benzamide compounds target Bcl-2 to promote apoptosis in cancer cells and reduce HIV-infected cell populations with latency-reversing agents.

Localized chitosan–polyalcohol delivery targets persister cells in biofilms, concentrating antimicrobials at infection sites while limiting systemic toxicity.

Specific R1–R6 substituents target PI3Kγ while limiting activity on other PI3K subtypes and off-target toxicity.

Specific pyrano[2,3-c]pyridine compounds target α-glucosidase inhibition to control postprandial glucose while addressing starch-related GI effects.

Separate oil phases help deliver tacrolimus through skin while the aqueous composition supports chemical stability and lower irritation.

Fluoropyrrolopyridine compounds inhibit ATR activity to address limited pathway targeting and induce synthetic lethality in ATM-deficient cancer cells.

High-fat emulsions can cause caking, fouling, and excess free fat; OSA starch stabilizes spray drying to produce powders below 3 wt% free fat.

This case combines 5-azacytidine with venetoclax and other agents to increase AML cell death for elderly and unfit patients.

Using a Wenker route with staged deprotection and hydrogenation, the process addresses impurity and yield losses during GDC-9545 scale-up.

An miR-27a-5p mimic inhibits the NF-κB pathway to reduce intestinal lesions and symptoms during C. difficile infection.

Localized backbone and base modifications improve oligonucleotide stability while preserving TLR7 response, potentiating TLR8 sensing, and reducing immunosuppression.

BF3-binding indole compounds bypass ligand-site targeting to inhibit AR activity, addressing anti-androgen resistance and Kennedy's disease.

Precursor-based antioxidant support uses polydatin and acetylcysteine to address direct glutathione degradation and limited bioavailability.

Defined PcrV epitopes enable anti-PcrV antibodies to block T3SS function and protect against infection at lower doses.

A low-molecular-weight polyester solution lowers injection force and tissue irritation while forming a cohesive mass for drug release over days to a month.

Spray-dried or hot-melt-extruded amorphous enzalutamide with a concentration-enhancing polymer improves solubility and absorption in tablets.

These CD19-specific CARs avoid rituximab binding while retaining expression and activity, enabling immediate CAR-T therapy after rituximab treatment.

Tumor-vessel normalization through phosphatidylcholine improves blood flow, drug delivery, and immune-cell infiltration while sparing normal vessels.

Co-amorphous drug formulations combine anti-cancer agents with beta-lactoglobulin to boost solubility while preventing re-crystallization during storage.

Structural modifications to the 1,2,4-triazole moiety reduce CYP3A4 inhibition while preserving antiangiogenic activity for safer drug combinations.

Modifying p53 stability via positive charge tails improves phase separation, resolving instability issues to enhance anti-tumor efficacy.

Non-steroidal compounds selectively bind androgen receptors to improve muscle strength and bone density without increasing prostate cancer risk.

Volatile siloxanes in a composite gel matrix resolve thermal instability and stickiness while maintaining therapeutic efficacy of celecoxib.

Lomitapide titration reduces triglycerides and pancreatitis risk while monitoring liver enzymes.

Antagonists block IL-17B signaling to reduce tumor growth and metastasis in breast and pancreatic cancer models.

Merging two initial doses into one heightened injection improves patient compliance while maintaining therapeutic efficacy and consistent plasma concentrations.

Targeting the NAE1 gene in salmonids to enhance resistance against infectious pancreatic necrosis virus.

Nanoassembled complexes use a hydrophilic polymer shell to stabilize avidin-biotin structures in aqueous environments.

A miRNA pharmaceutical composition promotes neuronal differentiation while inhibiting astrocyte generation.

Macrocyclic dihydropyridone compounds inhibit factor XIa while resolving the contradiction between inhibition efficacy and gut permeability.

Replacing flammable electrolytes with non-volatile glycerol-based polycarbonates eliminates thermal runaway risks while maintaining energy density.

Novel diazabicyclooctanone compounds inhibit serine beta-lactamases to restore antibiotic efficacy.

Replacing castor oil with sesame oil and benzyl benzoate reduces viscosity for easier injection while maintaining stability.

Frizzled extracellular cysteine-rich domain protein increases bone mass while avoiding side effects from full-length receptors.

Heterocyclyl compounds inhibit Toll-like receptors to reduce toxicity while maintaining anti-inflammatory efficacy.

Specific substitution patterns enable sustained release at lower polymer concentrations, reducing dosage form size for easier swallowing.

A tiotropium solution formulation uses controlled ethanol and bisulfite stabilizers to maintain chemical stability in HFA propellants.

8.4% sodium bicarbonate binds calcium to prevent clots, eliminating bleeding complications from heparin.

A microRNA-675 delivery system downregulates DUX4 expression using RNA interference mechanisms.

Local injection of amobarbital-loaded hydrogel sustains drug release to protect mitochondria from dysfunction, preventing early disc degeneration progression.

A bioerodible ocular insert releases vorolanib to maintain therapeutic levels for up to 180 days.

Novel CFTR modulators correct protein trafficking and enhance channel gating activity.

Compound 1 modulates GABA receptors to reduce tremor amplitude, addressing inadequate efficacy of current treatments.

Crystalline potassium salt of 1-ethyl-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)piperidine-4-sulfonamide enhances stability and solubility.

Administering protein inhibitors reduces lipid accumulation in hepatocytes to treat non-alcoholic fatty liver disease.

Encapsulating NMDA antagonists in biodegradable microparticles enables sustained drug release over weeks.

Merging anti-fibrotic pirfenidone with anti-inflammatory nintedanib reduces collagen deposition and inflammation while maintaining safety.

Isoflavones inhibit glycosaminoglycan synthesis, bypassing blood-brain barrier limits of enzymatic replacement therapy.

Segmented biliverdin reductase proteins modulate protein kinase C-delta and ERK complex activity to treat autoimmune disorders and cancer.

Topoisomerase inhibitors unsilence the paternal Ube3a allele to restore protein levels and treat Angelman syndrome neurological deficits.

Composite natural extracts inhibit renal cancer cell growth while enhancing kidney function through enzymatic action.

Granular methylfolate composition with acetyl L-carnitine salt maintains therapeutic efficacy through stable crystalline formulation.

Nanoscale palygorskite and montmorillonite nanoclays reduce melanoma cell viability while minimizing adverse side effects from conventional treatments.

Adding magnesium hydroxide carbonate or arginine neutralizes acidic conditions, preventing degradation of the azole-based antifungal agent during storage.

Injectable microsphere formulations using biodegradable polymers sustain ibrutinib release, resolving low oral bioavailability and frequent dosing requirements.

In vitro culture of undifferentiated Mimosa pudica cells produces a mimosine-depleted preparation with potent antioxidant activity.

A Scutellariae radix compound inhibits the mitochondrial oxidative phosphorylation pathway to block tumor cell energy production.

Targeting ADAR1 reduces adenosine-to-inosine editing, slowing chronic myeloid leukemia progression by enhancing let-7 microRNA levels.

Segmented PLGA microparticles and fibrin gel release therapeutics to overcome impaired osteoblast differentiation in diabetic fractures.

Ferrous amino acid chelate exploits transferrin receptors to suppress lung and liver tumors while sparing normal cells.

Antifibrotic agents combined with biomarker profiling to assess patient response in progressive interstitial lung diseases.

Heterobifunctional small molecules engage the androgen receptor and disease-dependent proteins to form selective ternary complexes.

A polyhydroxyalkylammonium sodium channel blocker increases mucosal hydration by inhibiting epithelial sodium absorption.

AGMA-1 polymer blocks viral attachment at the portal of entry, addressing limited vaccine coverage.

Enantiopure BDDE cross-links hyaluronic acid to resist enzymatic degradation while maintaining structural integrity.

Modulating GABARAP expression levels to induce immunogenic cell death and activate antitumor immunity.